Can an IDO/PD-L1 com­bo ever work? No­vo-backed com­pa­ny spells out how in biotech's lat­est IPO fil­ing

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Add an­oth­er biotech to the horde of com­pa­nies aim­ing to make their Nas­daq de­buts be­fore the cal­en­dar turns to 2022.

Copen­hagen’s IO Biotech filed its SEC pa­per­work late last week, pen­cil­ing in $100 mil­lion for its ini­tial of­fer­ing. The move comes about nine months af­ter the No­vo Seeds-backed com­pa­ny pulled in a $154.5 mil­lion Se­ries B in Jan­u­ary to ad­vance its im­mune-mod­u­lat­ing IDO and PD-L1 can­cer vac­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER